Indeed, studies in various solid malignancies have shown that blockade of the axis with monoclonal antibodies or CSF-1R inhibitors can lead to reduced myeloid numbers at the tumor site [165,166] and increased numbers of macrophages with antitumor activity [167]. This evidence concerns the gene CSF1R and neoplasm.